Exelixis, Inc. $EXEL Shares Purchased by Milestone Asset Management LLC

Milestone Asset Management LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 828.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,792 shares of the biotechnology company’s stock after buying an additional 65,841 shares during the period. Milestone Asset Management LLC’s holdings in Exelixis were worth $3,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in shares of Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after acquiring an additional 2,926,884 shares during the period. Norges Bank acquired a new stake in Exelixis in the 2nd quarter valued at approximately $122,099,000. Qube Research & Technologies Ltd grew its stake in shares of Exelixis by 120.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock valued at $134,306,000 after buying an additional 1,665,110 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Exelixis by 42.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after acquiring an additional 1,580,567 shares in the last quarter. Finally, Prudential Financial Inc. increased its stake in Exelixis by 776.8% during the 2nd quarter. Prudential Financial Inc. now owns 1,468,865 shares of the biotechnology company’s stock worth $64,740,000 after buying an additional 1,301,330 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity

In other news, EVP Patrick J. Haley sold 28,043 shares of Exelixis stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $42.58, for a total transaction of $1,194,070.94. Following the completion of the sale, the executive vice president directly owned 374,029 shares in the company, valued at $15,926,154.82. The trade was a 6.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mary C. Beckerle sold 24,622 shares of Exelixis stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares of the company’s stock, valued at $896,463.40. The trade was a 53.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 245,235 shares of company stock valued at $10,490,600 over the last quarter. 2.82% of the stock is currently owned by company insiders.

Exelixis Stock Up 0.1%

Exelixis stock opened at $46.64 on Thursday. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62. The firm has a market capitalization of $12.50 billion, a PE ratio of 19.68, a P/E/G ratio of 0.84 and a beta of 0.40. The firm’s 50-day simple moving average is $41.53 and its 200 day simple moving average is $40.88.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $597.76 million during the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the company posted $0.47 EPS. On average, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the subject of several recent research reports. Leerink Partnrs upgraded Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. Stifel Nicolaus set a $43.00 price target on shares of Exelixis in a research report on Wednesday, November 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Finally, Morgan Stanley lifted their price objective on shares of Exelixis from $44.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Exelixis presently has an average rating of “Moderate Buy” and a consensus price target of $45.74.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.